Abstract-The purpose of the presented work is to examine the response of engineered cartilage to a transient, 2-week application of anabolic growth factors compared to continuous exposure in in vitro culture. Immature bovine chondrocytes were suspended in agarose hydrogel and cultured for 28 days (Study 1) or 42 days (Study 2) in chondrogenic media with TGF-b1, TGF-b3, or IGF-I either added for only the first 14 days in culture or added to the media for the entire study period. In both studies, there were no statistical differences in tissue mechanical or biochemical properties between the growth factors on day 14. In Study 1, growth factor removal led to a significant and drastic increase in Young's modulus and glycosaminoglycans content compared to continuously exposed controls on day 28. In Study 2, both TGF-b1 and b3 led to significantly higher mechanical properties and collagen content vs. IGF-I on day 42. These results indicate that the rapid rise in tissue properties (previously observed with TGF-b3 only) is not dependent on the type but rather the temporal application of the anabolic growth factor. These findings shed light on possible techniques to rapidly develop engineered cartilage tissue for the future treatment of osteoarthritis.
INTRODUCTION
Articular cartilage is the load-bearing material of diarthrodial joints, with excellent friction, lubrication, and wear-resistance characteristics. 30 The tissue obtains its ability to resist high compressive loads from the balance between the osmotic swelling pressure of proteoglycans, highly charged macromolecules comprised glycosaminoglycans (GAGs), and the tension in the collagen fibers that comprise the majority of the tissue matrix. 20 Due to its avascular and aneural nature, articular cartilage possesses poor intrinsic healing capability, with localized damage to the tissue eventually worsening to severe damage to the cartilage that is classified as osteoarthritis (OA). 11 The current ''gold standard'' treatment for end-stage OA is total joint arthroplasty 38, 41 that involves the replacement of the damaged bone and cartilage with a synthetic implant. This procedure is extremely effective in relieving symptoms and restoring patient quality of life, but is usually prescribed for late-aged patients to be conservative with implant durability and lifespan. Therefore, for younger patients with localized cartilage damage that has not progressed to the entire joint, orthopedic surgeons will employ techniques that aim to generate repair tissue (i.e., microfracture, autologous chondrocyte implantation) or to transplant healthy cartilage to the affected area (i.e., mosaicplasty). 7, 15, 43 Though all of these techniques can minimize pain and restore joint motion in the short-term (£2 years) post-operatively, new studies have discovered deteriorating clinical outcomes at longer follow-up times (>5 years post-operatively) for all techniques. 28, 29, 42 The limitations of traditional treatment motivate cartilage tissue engineering efforts to create a biological replacement cartilage as a future treatment for OA. Such a replacement tissue would grow and remodel with the patient, broadening the age range of eligible patients.
The general paradigm for tissue engineering is to combine a cell source, scaffold, and various stimuli to generate engineered tissue that replicates the in vivo properties of the native tissue. 14 The majority of the cartilage engineering research performed in our laboratory utilizes primary chondrocytes (freshly isolated and without passaging) seeded in an agarose hydrogel scaffold. Agarose has been known for its well-documented ability to promote and maintain the chondrocyte phenotype in long-term in vitro cultures. 3, 8, 26 Recently, however, clinical trials have shown the potential for agarose in cartilage regeneration, with an autologous human chondrocyte-laden agarose-alginate hydrogel in Phase III clinical trials (http://clinicaltrials. gov/ct2/show/NCT00945399) and 2-year follow-up data showing good clinical outcomes with no gross rejection of the scaffold apparent in the patients. 39 To stimulate matrix formation, research has focused on the use of growth factors with serum-free culture media due to the variability of serum 17, 36 and its negative effects on chondrocyte phenotype. 31 Three growth factors that have been found to stimulate matrix synthesis in engineered cartilage are transforming growth factor (TGF) isoform b1 and b3, as well as insulin-like growth factor I (IGF-I). 9, 13, 25, 48 In addition, the combination of applied mechanical stimuli and the use of these growth factors has shown to synergistically increase matrix synthesis and tissue properties in engineered cartilage constructs. 22, 25 In general, the studies in the literature examining the effects of growth factors on engineered cartilage present the protein to the tissue continuously throughout culture. However, during the rapid matrix formation that occurs during cartilage development and wound healing, different growth factors are up/ down-regulated at different times. 2, 6, 12, 45 Indeed, in our laboratory's previous research, it was found that short-term, transient supplementation of TGF-b3 resulted in significantly greater matrix synthesis by agarose encapsulated chondrocytes than continuous supplementation in in vitro culture. 22 Therefore, we sought to see if this phenomena transfers to other anabolic molecules and to confirm the importance of time in applied growth factor stimulation for cartilage tissue engineering. We hypothesized in this study that a 2-week application of TGF-b1, TGF-b3, or IGF-I followed by culture without any further exposure to any growth factors will lead to significantly greater matrix formation than continuous supplementation of the growth factors. This methodology was based on previous work by our laboratory and collaborators in the literature. 9, 22 As tissue engineering is focused on the functional tissue properties and behavior, we evaluated the engineered tissue's mechanical and biochemical properties over time in culture.
MATERIALS AND METHODS

Experimental Design
Two studies were performed to characterize the response of engineered cartilage to the growth factors TGF-b1, TGF-b3, and IGF-I. In both studies, engineered cartilage constructs were created from 2% weight/volume agarose containing 30 million chondrocytes/mL. These constructs were cultured in a serum-free media known to foster cartilage tissue formation.
9 Study 1 examined the effects of continuous vs. transient (2 weeks) growth factor treatment on the engineered cartilage mechanical and biochemical characteristics over 28 days to examine any similarities between the response of engineered cartilage to TGF-b1 and IGF-I to the known response to TGF-b3. 9 Non-growth factor supplemented controls were cultured from a separate, multiple animal, mixed chondrocyte isolation (same as the protocol described below) that was later found to be similarly responsive to growth factor treatment (data not shown). Once these results were obtained and analyzed, Study 2 utilized separate, freshly cast constructs and examined the transient application of the growth factors over a 42-day period to study the differences between the growth factors with additional time in culture.
Creation and Culture of Agarose Constructs
Bovine articular chondrocytes were isolated via enzymatic digestion as described previously. 34 Briefly, chondrocytes were isolated from calf carpometacarpal joints from an 11-h digestion of full thickness cartilage slices in 390 U/mL type V collagenase (Sigma Aldrich, St. Louis, MO) using 7.5 mL/g tissue of high glucose DMEM with buffers 27 and 5% fetal bovine serum. Cells were resuspended and mixed with molten type VII agarose (Sigma) in phosphate-buffered saline (PBS, Sigma) at 40°C to yield a 2% agarose suspension with 30 9 10 6 chondrocytes/mL. This suspension was cast between two glass plates and allowed to cool for 20 min. Disks were cored out (B 4.0 9 2.3 mm) and cultured at 37°C and 5% CO 2 in 35 mL of chondrogenic media (high glucose DMEM, 1% ITS+, 0.1 lM dexamethasone, 110 lg/mL sodium pyruvate, 50 lg/mL L-proline, 50 lg/mL ascorbate-2-phosphate, sodium bicarbonate, and antibiotics 9 ). For both studies described above in ''Experimental Design'' section, either 10 ng/mL TGF-b3, 9 10 ng/mL TGF-b1, 25 or 100 ng/mL IGF-I 13 (R&D Systems, Minneapolis, MN) was added with each media change. For Study 1, growth factor supplementation was given either continuously or for a 2-week period and then ceased. For Study 2, growth factors were added to the culture media for only the first 2 weeks in culture. For all studies, day 0 mechanical testing was performed prior to any growth factor treatment. Constructs (n = 6 per group) were then removed from culture on every 2 weeks for evaluation of mechanical properties and biochemical composition.
Mechanical Testing
Mechanical testing was performed in unconfined compression between two impermeable platens in a custom material testing device as previously described. 26 Constructs were first equilibrated under a creep tare load of~0.02 N followed by a stress relaxation test with a ramp displacement of 1 lm/s to 10% strain (based on the measured post-creep thickness). After equilibrium was reached (2000 s), a sinusoidal displacement of 40 lm amplitude was applied at 1 Hz. Compressive Young's modulus (E Y ) was determined from the equilibrium response of the stress relaxation test by dividing the equilibrium stress (minus the tare stress) by the applied strain. Dynamic modulus (G*) at 1 Hz was calculated from the ratio of the measured stress amplitude and the applied strain amplitude of the dynamic loading. Following mechanical testing, samples were stored at 220°C for biochemistry or processed for histology (Study 2 only).
Histology
Samples were fixed in acid-ethanol-formalin for 48 h at 4°C, dehydrated in a graded series of ethanol, cleared, embedded in Tissue Prep embedding media (Fisher Scientific, Pittsburgh, PA), and sectioned at 6 lm. Sections were then either stained with Safranin O (with a Fast Green counterstain) to view GAG distribution or Picrosirius Red to visualize the collagen network.
Biochemical Analysis
The samples were thawed, weighed wet, lyophilized, reweighed dry, and digested for 16 h at 56°C with 1 mg/mL proteinase K (EMD Biosciences, San Diego CA) in 50 mM Tris-buffered saline containing 1 mM EDTA, 1 mM iodoacetamide, and 10 lg/ml pepstatin A (Sigma). 37 These digests were used to determine sample GAG content via the 1,9-dimethylmethylene blue (Sigma) dye-binding assay 10 and for DNA content via the PicoGreen assay (Invitrogen, Carlsbad, CA). The overall collagen content was measured using orthohydroxyproline (OHP) colorimetric assay. 44 Collagen content was calculated by assuming a 1:10 OHP-to-collagen mass ratio. 16 If necessary, assays were adapted for use in micro-titer plates. The GAG and collagen contents were normalized to the construct wet weight and DNA content.
Statistical Analysis
Statistics were performed using the Statistica (Statsoft, Inc., Tulsa, OK) software package. At least six samples were analyzed for each data point, with data reported as the mean and standard deviation. For mechanical and biochemical data, groups were examined using ANOVA with E Y , GAG, collagen, and DNA as the dependent variables and culture time and growth factor as the independent variables. Tukey HSD post hoc tests were carried out with statistical significance set at a = 0.05.
RESULTS
Study 1: Continuous vs. Transient Growth Factor Supplementation
After 14 days in culture, all constructs increased in their compressive Young's modulus (E Y , a measure of a material's resistance to a static compression at equilibrium) and dynamic modulus (G*, a measure of a material's resistance to a dynamic, oscillatory compression) (Fig. 1) . Similar increases in the GAG and collagen content were also observed (Table 1) . Constructs cultured in IGF-I possessed a lower average E Y than TGF-cultured counterparts, but this was not statistically significant. The day 14 results of this study indicated that the growth factors at the concentrations selected for the study possessed a similar level of potency in spurring functional matrix development. On day 28, control (no growth factor) constructs did not significantly increase in mechanical properties compared to day 14, reaching values of E Y = 28.6 ± 12.1 kPa and G* = 0.328 ± 0.247 MPa (Fig. 1) . However, GAG and collagen content did increase with additional time in culture (Table 1 ). All growth factor treated groups significantly increased in mechanical properties and measured matrix proteins. However, constructs released from growth factor treatment exhibited significantly greater tissue properties that were up to~29 those of continuously treated tissues. The highest tissue properties for this study were achieved with transient growth factor treatment ( Fig. 1 ; Table 1 , maximum E Y~3 00 kPa, G*~3 MPa, GAG~5.5 ww%, collagen~2.5 ww%). DNA content for all constructs significantly increased by day 14, but remained steady afterward (Table 1) .
Study 2: Transient Growth Factor Supplementation in Extended Culture
Using a separate batch of chondrocytes isolated from different animals from Study 1, engineered cartilage constructs were created and cultured up to day 42. Compared to day 0 values, constructs after 14 days of growth factor treatment significantly increased in E Y (~45 vs.~8 kPa), G* (~0.15 vs.~0.03 MPa), GAG (~2.5 vs. 0.1 ww%), and collagen content (~1 vs.~0.2 ww%), with no significant differences between experimental groups ( Fig. 2; Table 2 ; p < 0.05). On day 28, constructs exhibited a~5-10-fold increase in mechanical properties depending on growth factor treatment, with the TGF-b3 group possessing the highest properties of all groups ( Fig. 2; Table 2 ; p < 0.05). With an additional 2 weeks in culture, both TGF-b treated tissues exhibited significantly higher E Y , G*, and collagen content than IGF-I treated tissues (p < 0.05) and attained physiologic values for E Y and GAG content compared to native cartilage. 24 DNA was found to increase after 14 days in culture~40% in all culture conditions and held steady afterward ( Table 2 ). Safranin O histology (Fig. 3) revealed intense localization of proteoglycans to the pericellular region for constructs cultured with IGF-I at day 14 through day 42. Constructs cultured with either TGF-b isoform exhibited more diffuse proteoglycan distribution throughout time in culture. Picrosirius Red histology (Fig. 4 ) of constructs cultured with IGF-I showed formation of a collagen matrix with a sharper, more defined border between chondrocyte clusters at day 14 and day 28. At these time points, constructs cultured with either TGF-b1 or TGF-b3 exhibited qualitatively more diffuse collagen staining. By day 42, however, no qualitative differences were noted in the distribution or structure of collagen staining between the growth factor groups.
DISCUSSION
The primary purpose of this study was to analyze the effects of a transient vs. prolonged exposure of anabolic growth factors on tissue-engineered cartilage with the goal to trigger the initial steps of rapid tissue remodeling that occurs during development and wound healing. In well-defined, serum-free chondrogenic media, all three growth factors stimulated cartilage tissue formation by day 28 superior to previously attained properties with serum-based media. 27 When the growth factor application was ceased, all of the tissue constructs responded with a rapid increase in tissue properties resulting in significantly higher tissue properties than continuously exposed controls, affirming our hypothesis. For the 2-week exposure, the similar trends between the three growth factors tested implies that the rapid increase in tissue properties is not dependent on the anabolic growth factors used in this study, but rather the temporal application itself. This may be related to the transient profile of growth factors observed in vivo during wound healing 2, 6, 45 or during fetal development. 12 This ''on-off switch'' 0.047 ± 0.006* TGF-b1 7.41 ± 0.81* mechanism for rapid matrix synthesis is not well studied in the literature and opens a new avenue for further research. In our data, we observed that similar increases in the gross composition of GAG and collagen across the TGF-b and IGF-I groups did not necessarily correlate to similar increases in mechanical properties. Though the effect of the transient exposure was much greater than the effect of the different growth factors, this is explained by findings in the literature that IGF-I and TGF-b isoforms stimulate functional matrix formation in chondrocytes/cartilage differently and result in differing changes in the mechanical properties. 1, 49 The use of TGF-b1 or -b3 led to tissues with significantly greater equilibrium and dynamic compressive properties and collagen content compared to those cultured with IGF-I after 42 days in culture (Study 2). This difference can be explained by the well-known increase in collagen synthesis and collagen cross-link formation that leads to increased cartilage tensile properties (which play a role in the dynamic modulus 18 ) that occurs with administration of TGF-b isoforms but not with IGF-I. 1, 49 On a morphological scale, IGF-I has been shown in the literature to increase pericellular matrix formation, whereas TGF-b was found to increase extracellular matrix formation. 46 This was apparent in the proteoglycan staining of Study 2 constructs (Fig. 3) . Therefore, to explain our data, it would appear that changes in the type, size, structure, and/or spatial location of the matrix components are responsible for the disparity between the gross biochemical composition and the mechanical properties in our studies. Overall, the results of our studies confirm the differences in the stimulation of chondrocytes with exposure to TGF-b isoforms and IGF-I, but show that the action of the growth factors can be further modulated by the timing of their exposure.
Comparing the two TGF-b isoforms, TGF-b3 induced higher mechanical properties than TGF-b1 on day 28 in Study 2, but no differences were observed in the mechanical properties in Study 1, the histology of Study 2, or in the biochemical content in either study. In addition, day 42 results for both TGF-b isoforms were statistically similar. Though little literature exists for chondrocyte/cartilage models, TGF-b3 can reduce scar tissue and induce more natural tissue regeneration in dermal wound healing models as compared to TGF-b1. 40 It is likely that similar, differential matrix formation may be occurring within the engineered cartilage in response to the TGF isoforms as well. Further studies are needed to qualify the exact differences in the response of chondrocytes between TGF b1 and b3. Likely, there are structural changes and changes in synthesis of other important cartilage proteins such as link protein and cartilage oligomeric matrix protein (COMP). Interestingly, in other preliminary studies (not shown), it was found that a second phase of TGF-b addition and removal did not re-stimulate matrix synthesis by the chondrocytes. This may be due to previously observed modulation of TGF-b signals by the presence of elaborated pericellular matrix. 47 The results of this study strongly indicate that a transient application of anabolic growth factors elicits greater matrix formation over prolonged supplementation. As tissue engineering progresses toward a clinical application, this rapid tissue growth with only 2 weeks of growth factors can lead to quicker tissue production with the added benefit of reduced production costs. Clearly, the rapid tissue growth in this study will not occur with growth factors or cytokines that elicit a response other than matrix formation (e.g., FGF-2, PDGF 5,35 ). Our laboratory has administered IL-1a, which initiates a catabolic response from chondrocytes, to engineered cartilage and found that the cellular response depended heavily on when the cytokine was added during the culture period. 23 In contrast to our results presented in this article, Kalpackci et al. found no beneficial effect of intermittent TGF-b1 supplementation on the tissue properties of engineered fibrocartilage constructs, 19 implying a tissue-specific, temporal effect of growth factors. The age of the cells may also play a role as experiments in our laboratory with mature bovine and canine chondrocytes found no benefit of a transient growth factor treatment. 4, 32, 33 It is clear that the macro-scale measurements utilized in the present work, though insightful, are not sufficient to fully elucidate the differences occurring within the cells and tissues with exposure to TGF-b1, TGF-b3, and IGF-I. Molecular biology techniques are needed to understand the signal transduction underlying the observed results. In addition, determination of specific matrix molecules, size of matrix molecules, and imaging techniques to observe structure (e.g., electron microscopy to view matrix fiber structure, proteoglycancollagen interactions) and quantitative matrix distribution (e.g., FT-IRIS 21 ) would allow better understanding of the differences in the tissue formed between the different growth factors used. This need is evident in our study as the significant increases in proteoglycan and collagen in the control specimens over time did not lead to increased mechanical properties in contrast to growth factor treated tissues. This implies that although the total content of the nongrowth factor treated controls is the same, the type, size, and/or structure of the matrix proteins are likely different than those produced in constructs cultured with growth factors.
In conclusion, our results presented in this article indicate that the rapid rise in tissue properties previously observed with the 2-week application of TGF-b3 9, 22 is not dependent on the type but rather the temporal application of the anabolic growth factor. The type of growth factor utilized appears to influence the magnitude of tissue properties and likely the matrix composition and structure. The mechanisms behind these results are likely related to the observed rapid matrix formation during wound healing and fetal development. As cartilage tissue must be mechanically competent to perform its function in vivo, the presented results shed light on possible techniques to rapidly develop a load-bearing engineered cartilage tissue for the future treatment of OA.
